BASEL, Switzerland (Reuters) - Roche said again on Tuesday that it deemed its $93 per share offer for U.S. biotech group Genentech as fair, after a source familiar with the situation had said the two sides were in talks for a deal at a higher price.
0 Responses to Roche says latest Genentech bid is still fair